clonoSEQ Data at ASCO/EHA 2026 Reinforce MRD Leadership

What happened

Adaptive Biotechnologies presented over 30 studies at ASCO and EHA 2026 leveraging clonoSEQ MRD testing, underscoring its central role in hematology clinical practice and research. The data demonstrate clonoSEQ's utility in assessing novel therapies and guiding MRD-based patient care across blood cancers, aligning with the company's strategy to drive adoption through evidence and regulatory momentum. This reinforces the reimbursement moat and potential for volume growth, supported by FDA authorizations and broad Medicare coverage. While the Genentech collaboration termination reduced therapeutic optionality, the MRD diagnostics focus is validated by increasing biopharma and clinical adoption. The news supports the BUY thesis that clonoSEQ's entrenched position and expanding evidence base will drive durable growth and profitability.

Implication

Accumulation of evidence at major conferences solidifies clonoSEQ as the standard of care in heme MRD, expanding its TAM and strengthening the competitive moat, which reinforces the path to profitable growth and reduces disruption risk.

Thesis delta

The new data at ASCO and EHA provide additional proof points that clonoSEQ adoption is accelerating, particularly in pharma trials and clinical practice, de-risking the volume growth assumption in the BUY thesis and suggesting near-term catalysts remain on track. No fundamental shift; the thesis is strengthened.